Directory
Research PeptidesGROWTH HORMONE AXIS
Evidence grade D
CJC-1295 No DAC
Support comes from mechanism, cell and animal data and inference from related compounds; no human trials of this exact molecule.
- Strengths
- 5, 10 mg
- Also known as
- Modified GRF (1–29), Mod GRF 1–29, Tetrasubstituted GRF (1–29), CJC-1295 without DAC
- Molecule
- 29-amino-acid GHRH analog (peptide amide)
- Formula
- C152H252N44O42
- Mol. weight
- 3367.93 g/mol
- CAS
- 863288-34-0
Origin
A more stable version of sermorelin (GRF 1–29), the active fragment of growth-hormone-releasing hormone, with four amino-acid swaps (D-Ala2, Gln8, Ala15, Leu27). "CJC-1295 No DAC" is an informal sales name; ConjuChem's original CJC-1295 is the version with DAC.
How it works
Binds GHRH receptors on growth-hormone-producing cells in the pituitary, which then release growth hormone, raising IGF-1. The body's own brake (somatostatin) still works, so release stays pulsed. Without DAC it is short-acting, with a reported half-life of about 30 minutes.
What the research shows
No published human studies of this exact peptide were found. The well-known 2006 human CJC-1295 studies used the long-acting DAC version, so their results do not transfer. ConjuChem's 2005 rat and pituitary-cell work showed the modified backbone keeps GHRH-receptor activity, and older human studies tested related GRF analogs. Human pharmacokinetics, safe exposure range, immunogenicity and long-term IGF-1 effects are unknown.
Key studies
- Jetté et al., Endocrinology 2005 Rat pituitary cells and rats: the tetrasubstituted backbone keeps GHRH-receptor activity.
Safety findings
No human side-effect data exist for this molecule; sermorelin's labeled injection-site reactions, flushing and headache are a class reference only. FDA's compounding review listed immunogenicity, increased heart rate and a systemic flushing-type reaction as concerns for "CJC-1295" without separating the two forms.
Regulatory status
Not FDA-approved. FDA's compounding advisory committee voted against CJC-1295 free base (0–13) and acetate (1–12) in December 2024, and no lawful 503A pathway was confirmed as of October 2026. Prohibited at all times by WADA (S2.2.4 names CJC-1295).
Catalog notes
Available in 5 and 10 mg; the 10 mg strength has a certificate (lot CJC10-0803, 99.76% purity, COA7601), and none is published for 5 mg. Check the lot's certificate for the molecular weight: about 3368 g/mol indicates the No DAC form and about 3647 g/mol the DAC form.